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R a n d o m iz e d  T ria l  o f  B leom ycin ,  E top os id e ,  and
C is p la t in  C o m p a r e d  W ith  B leo m y c in ,  E to p o s id e ,  an d
C a r b o p la t in  in  G o o d -P ro g n o s is  M eta sta t ic  
N o n s e m in o m a to u s  Germ  Cell Cancer: A 
M u lt i in s t i t u t io n a l  M ed ica l  R esearch  C o u n c i l /E u r o p e a n  
O rgan iza t ion  for Research and Treatment of Cancer Trial
By A. Horwich, D,T. Sieijfer, S.D. Fossa, b.B. Kaye,
P.H.M. de Muider, D.P. Dearnaley, P.A.
Purpose: This prospective randomized multicenter 
trial was designed to evaluate the efficacy of carboplatin 
plus etoposide and bleomycin (CEB) versus cisplatin plus 
etoposide and bleomycin (BEP) in first-line chemotherapy 
of patients w ith good-risk nonseminomatous germ cell 
tumors.
Patients andM ethods; Between September 1989 and 
M ay 1993, a total of 598 patients with goad-risk non­
seminomatous germ cell tumors were randomized to re­
ceive four cycles of either BEP or CEB. In each cycle, the 
etoposide dose was 120 m g /m 2 on days 1, 2 , and 3, and 
the bleomycin dose was 30 U on day 2* BEP patients 
received cisplatin at 20  m g/m 2/d  on days 1 to 5 or 50 
m g /m 2 on days 1 and 2. For CEB patients, the carboplatin 
dose was calculated from the glomerular filtration rate 
to achieve a serum concentration x time of 5 mg/mL x 
minutes. Chemotherapy was recycled at 21-day intervals 
to a total of four cycles.
Results: Of patients assessable for response, 253 of 
268 (94.4%) of those allocated to receive BEP achieved
R.T.D. Oliver, M.H. Cullen, G.M. Mead, R. de W it,
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a complete response, compared with 227 of 260 (87.3%) 
allocated to receive CEB (P ~ .009). There were 30 treat­
ment failures in the 300 patients allocated to BEP and 79 
in the 298 allocated to CEB (log-rank x 2 = 26.9; P <  
.001), which led to failure-free rates at 1 year of 91%  
(95% confidence interval [Cl], 88% to 94%) and 77%  
(95% Cl, 72% to 82%), respectively. There were 10 
deaths in patients allocated to BEP and 27 in patients 
allocated to CEB (log-rank x* = 8.77; P = .003), which 
led to 3-year survival rates of 97% (95% Cl, 95% to 99%) 
and 90% (95% Cl, 86% to 94%), respectively.
Conclusion: With these drug doses and schedules, 
combination chemotherapy based on carboplatin was 
inferior to that based on cisplatin. This BEP regimen that 
contains moderate doses of etoposide and bleomycin is 
effective in the treatment of patients with good-progno- 
sis metastatic nonseminoma.
J Clin Oncol 15:1844“ 1852. © 1997 by American So­
ciety of Clinical Oncology.
C ISPLATIN-B ASED chemotherapy combinations are 
highly effective in the management of metastatic 
nonseminomatous germ cell tumors and a variety of such 
combinations are associated with long-term disease-free 
survival and presumed cure in approximately 85% of pa­
tients.1'5 The prognosis has been found to be better in 
patients with less extensive metastatic disease defined in 
a number of ways by different groups. For the purposes 
of this trial, the definition of eligibility was derived from 
an analysis of 795 patients treated for metastatic disease 
between 1982 and 1986.2 This showed that a good-prog-* 
nosis group could be defined as those who did not have 
metastases in liver, bone, or brain; who had relatively low
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tumor markers (human chorionic gonadotropin [HCG] <  
10,000 IU/L and alfa fetoprotein [AFP] <  1,000 KU/L); 
who had =s 20 lung masses; and whose maximum diame­
ter of metastatic disease was 10 cm in the abdomen or 
5 cm in the mediastinum or supraclavicular fossa. The 
predicted 3-year survival rate in this group was 94%.2
In view of the reduced toxicity of carboplatin compared 
with cisplatin with respect to gastrointestinal symptoms, 
renal damage, high-tone auditory loss, and peripheral neu­
ropathy, this drug was introduced into the management 
of patients with germ cell tumors.6'8 Results of pilot stud­
ies were promising. Of 121 patients with good-prognosis 
metastatic nonseminomatous disease treated with car­
boplatin, etoposide, and bleomycin (CEB) at the Royal 
Marsden Hospital between 1984 and 1990, there were 
only nine treatment failures and the cause-specific sur­
vival rate was 98% with a median follow-up duration of 
36 months.9 However, the prognosis was substantially 
worse in patients with more advanced categories of meta­
static disease,8 and in view of the curability of this tumor 
in good-prognosis patients, it was felt that the efficacy 
of carboplatin combinations required rigorous evaluation 
before being generally accepted as the standard of care. 
Therefore, the United Kingdom Medical Research Coun­
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cil (MRC) Testicular Tumour Working Party designed a 
prospective randomized trial, which was launched in 
1989. The Genitourinary Group of the European Organi­
zation for Research and Treatment of Cancer (EORTC) 
joined the trial in January 1991.
The trial design was informed by results of studies 
available at that time suggesting that bleomycin may not 
be an essential component of the combination chemother­
apy of patients with good-prognosis germ cell tu­
mors,3,10,11 and for this reason, together with the aim to 
reduce toxicity further, the dose of bleomycin in both 
arms of the trial was reduced to 30 U per cycle.
A synchronous trial was performed by the Memorial 
Sloan-Kettering Cancer Center and the Southwestern On­
cology Group (SWOG) based on 270 patients whose 
treatment was randomized between four cycles of etopo­
side plus cisplatin (EP) or four cycles of etoposide plus 
carboplatin (EC). In this trial, EC was given on a 28-day 
cycle and the carboplatin dose in 108 of 130 patients 
allocated to receive EC was 500 mg/m2 on day 1 of 
each cycle.12 This trial showed that the carboplatin-based 
combination led to inferior relapse free-survival, but no 
difference in overall survival was detected.
PATIENTS AND METHODS
Eligibility
Patients with histologically confirmed nonseminomatous germ cell 
tumors, or seminoma with unequivocally raised AFP levels, were 
eligible if they satisfied all of the following criteria, which were 
derived from prognostic factor analyses by the MRC2 and EORTC 
and defined a group that consisted of two thirds of patients with 
metastatic nonseminoma who had an expected progression-free sur­
vival rate at 1 year of 90%. All patients had had testicular primary 
tumors and had adequate renal function (glomerular filtration rate 
[GFRJ >  50 mL/min). Criteria for entry were abdominal mass at 
most 10 cm in maximum transverse diameter; supraclavicular and 
mediastinal masses at most 5 cm in diameter; less than 20 lung 
metastases; no liver, bone, or brain metastases; and AFP level less 
than 1,000 KU/L and HCG level less than 10,000 IU/L.
Patients were randomized through the MRC Cancer Trials Office 
(CTO) in Cambridge and the EORTC Data Center in Brussels. Ran­
domization was stratified by participating center. Data management 
was performed in both randomizing centers, and the data were trans­
ferred to the MRC CTO for interim and final analyses.
Treatment
Chemotherapy consisted of four cycles at 2 1 -day intervals of either 
bleomycin, etoposide, and cisplatin (BEP) or CEB. The BEP schedule 
gave etoposide 120 mg/m2 on days 1, 2, and 3 and bleomycin 30 U 
on day 2 only; cisplatin was given to a total dose of 100 mg/m2 divided 
over 2 or 5 days. The CEB schedule was identical, except for the 
replacement of cisplatin by carboplatin. The initial carboplatin dose 
was that required to achieve an area under the concentration-time curve 
(AUC) of 5 mg/mL X  minutes,9,13 Thus, for GFR based on EDTA 
clearance, the recommended dose was 5 X  (GFR + 25) mg; for GFR
based on creatinine clearance, the dose was 10% lower. Carboplatin 
dose was escalated through successive cycles when the day 16 platelet 
count was more than 150 X  109/L and WBC count greater than 1.5 
X  109/L. Following chemotherapy, excision of residual masses greater 
than 2 cm was considered in patients with normal markers, with smaller 
masses being watched and excised only if persistent. Treatment on 
relapse was at the clinician’s discretion.
Statistical Considerations
The main end point of the trial was failure-free survival, with 
failure being defined by serial rising markers, the finding of residual 
undifferentiated malignancy in the resected surgical specimen, the 
appearance of new metastases or the noncystic enlargement of exis­
tent masses, or death. Response to chemotherapy and overall survival 
were also recorded.
The trial was designed as an equivalence trial. Given the antici­
pated toxicity savings with carboplatin-based therapy and the as­
sumption that most CEB failures would respond favorably to cis- 
platin-based salvage therapy, some reduction in the failure-free rate 
was considered acceptable. The target accrual was a minimum of 
450 patients to enable an 8% to 10% difference in failure-free rate 
to be excluded reliably (90% power) assuming a failure-free rate at 
1 year on BEP of 90%. An independent data-monitoring committee 
(DMC) reviewed the data after this target had been reached to advise 
on further continuation of the trial to detect smaller differences in 
the failure rate. They recommended against further accrual and the 
trial was formally closed in May 1993.
Failure-free survival curves were calculated using the Kaplan- 
Meier method and compared using the log-rank test. Treatment ef­
fects are summarized via the hazards ratio (HR); an HR greater than 
1 indicates benefit to BEP. Categorical data were analyzed using 
standard x 2 tests with tests for trend across ordered categories where 
appropriate.
RESULTS
Randomization began via the MRC in September 1989, 
and the EORTC joined in January 1991. The rapid accrual 
meant that few events were observed while the trial was 
open. The final decision to close the trial was made in 
May 1993, when a total of 598 patients had been random­
ized: 300 allocated to receive BEP and 298 allocated to 
receive CEB. Patients were entered from 46 centers in
10 countries. The median follow-up time of surviving 
patients is approximately 3 years. Eighty percent of pa­
tients in each treatment group have been monitored for 
at least 2 years.
Pretreatment characteristics are listed in Table 1, and 
are well balanced between the treatments. Overall, 13% 
of patients had raised markers as the only sign of disease 
and a further 53% had disease confined to the paraaortic 
nodes.
Treatment Received
Of 300 patients allocated to receive BEP, full treatment 
data are available on 297, of whom 271 (91%) received 
the full four cycles of BEP. Of the 26 who did not, one
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Table 1. Pretreatment Characteristics by Treatment Allocated
Allocated Treatment
Allocated Treatment
BEP CEB
BEP CEB
Characteriitic No. % No. % CliuJudm ihlic No. % No, %
Age, years Maximum diameter of neck mass
_ ■
<  20 18 6 26 9 (cm)
20-29 135 45 135 46 None 293 98 281 95
30-39 111 37 102 34 <  2 1 0 4 1
S: 40 34 11 33 11 2-5 5 2 10 3
Primary histology No, of lung metastases
W V
MTI 100 33 97 33 None 201 68 205 70
MTT 23 8 16 5 1 "4 71 24 58 20
MTU 120 40 124 42 5-19 22 8 30 10
TD 22 7 29 10 ^  20 2 1 1 0
Other 31 10 29 10 Royal Marsden Stage*
AFP level ( OJ/L) IM 36 12 37 13
<  100 227 77 225 76 II 151 51 154 53
100-499 40 14 52 18 III 14 5 13 4
500-999 21 7 12 4 IV 95 32 89 30
^  1,000 7 2 7 2 Indiana Classification*!
P-HCG level IU/L) Minimal disease
<  100 215 3 200 68 1 36 12 37 13
100-999 53 18 71 24 2 4 1 4 1
1,000-4,999 21 7 22 7 3
5,000-9,999 5 2 1 0 (a) <  3 in maximum
s= 10,000 2 1 1 0 transverse diameter 90 30 81 28
Maximum diameter of abdominal (b) s: 3 cm in maximum
mass (cm) transverse diameter 59 20 72 25
None 79 27 78 27 4 61 21 58 20
<  2 44 15 44 15 Subtotal 250 84 262 86
2-5 153 52 149 51 Moderate disease
5-10 18 Ó 23 8 5 2 1 1 0
>  10 3 1 0 0 6 34 11 34 12
Maximum diameter of Subtotal 36 12 35 12
mediastinal mass (cm) Advanced disease
None 2 77 93 271 92 7 2 5 2
<  2 10 3 9 3 8 3 1 1 0
2-5 12 4 15 5 9 0 0 0 0
Subtotal 10 3 6 2
Total 300 100 298 100
* Nine patients (4 BEP, 5 CEB) were not classifiable on the Royal Marsden or Indiana University staging systems.
t  Only total lung metastases were recorded, so they have been translated for the Indiana University Classification20 as follows: :£ 9, equivalent to <  5 
per lung field; 10-20, equivalent to 5-10 per lung field; >  20, equivalent to >  10 per lung field,
patient failed to attend and received no chemotherapy; Of 298 patients allocated to receive CEB, full data are
six stopped after three cycles and went for early surgery; available on 295, of whom 277 (94%) received the full
two stopped after three cycles having achieved a rapid four cycles of CEB. Of the 18 who did not, six patients
response; nine changed to CEB because of renal, cardiac, stopped after three cycles and received no further chemo-
or ototoxicity; one received CEB in cycle 1 in error; one therapy— three of these patients went for early surgery,
died after the first cycle from a small bowel infarction; two had achieved a rapid response, and one patient failed
two switched to more intensive treatment because of lack 
of marker response; and four received alternative treat­
ment throughout— two of these received CEB, one 
through patient choice and one through administrative 
error.
to attend for the fourth cycle. Seven patients switched 
to more intensive treatment because of lack of marker 
response, and one patient died after the first cycle with 
the postmortem examination unable to establish the cause. 
One received BEP in cycle 2 in error, and three patients
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Table 2. Response
»
Allocated Treatment
BEP CEB
Response No. % No. %
Complete response 253 87.2 227 78.3
To ch alone 180 62.0 171 59.0
To eh + S 73 25.2 56 19.3
Incomplete response 15 5.2 33 11.4
Undiff cancer resected 11 3.8 29 8.2
Inadequate marker response 4 1.4 9 3.1
Not assessable (PMNM) 22 7.6 30 10.3
Unknown 10 8
Total 300 298
Abbreviations: ch, chemotherapy; S, surgery; Undiff, undifferentiated; 
PMNM, persisting mass(es} with normal markers.
received alternative treatment throughout— one of these 
received BEP by patient request.
Response
Responses to chemotherapy with or without surgery 
are listed in Table 2. Complete response is defined as 
either complete remission on chemotherapy alone or com­
plete resection of residual masses that contain only necro­
sis/fibrosis or mature (differentiated) teratoma. Patients 
with raised markers, viable (undifferentiated) tumor in the 
resected mass, or death while on treatment are considered 
incomplete responders. Of those patients assessable for 
response (ie, excluding those patients in whom residual 
masses were not excised), 94.4% of patients allocated to 
receive BEP and 87.3% of patients allocated to receive 
CEB achieved a complete response as described earlier, 
a difference that is statistically significant (P = .009).
Failure-Free Survival
The failure-free survival curves for all randomized pa­
tients according to allocated treatment are given in Fig 
1. The HR of 2.75 (95% confidence interval [Cl], 1.88 
to 4.03) corresponds to an absolute difference in failure- 
free rates at 1 year of 14%, with a 95% Cl of 8% to 
25%. There were 30 treatment failures in the 300 patients 
allocated to receive BEP and 79 in the 298 patients allo­
cated to receive CEB (log-rank %2 = 26.9; P <  .001), 
which led to failure-free rates at 1 year of 91% (95% Cl, 
88% to 94%) and 77% (95% Cl, 72% to 82%), respec­
tively.
The difference in failure-free survival was more 
marked in patients with stage III or IV disease than in 
patients with stage I marker-positive or stage II disease. 
A formal test of heterogeneity of treatment effect by stage 
was not significant (x 2 — 2.74; P = .09), although there
were 21 failures among 191 patients with stage IM or II 
allocated to receive BEP, compared with 46 failures 
among 196 allocated to receive CEB (HR = 2.3; 95% 
Cl, 1.3 to 3.4). In stage III/IV, there were nine failures 
among 109 patients allocated to receive BEP, compared 
with 33 failures among 102 allocated to receive CEB (HR 
= 4.2; 95% Cl, 2.2 to 7.8).
Table 3 lists a summary of failure and salvage data. 
Approximately one third of patients who failed to respond 
to initial chemotherapy with either BEP or CEB were 
disease-free at the time of analysis; this proportion may 
decrease with longer follow-up evaluation.
Survival
Survival curves are given in Fig 2. A total of 10 deaths 
have been reported in patients allocated to receive BEP 
and 27 in patients allocated to receive CEB, a difference 
that is statistically significant (log-rank x~ — 8.77; P = 
.003; HR = 2.65; 95% Cl, 1.39 to 5.05). The 3-year 
survival rates were 97% (95% Cl, 95% lo 99%) and 90% 
(95% Cl, 86% to 94%), respectively, a difference of 7% 
(95% Cl, 1% to 11%).
Carboplatin Dose
The initial carboplatin dose given was, on average, 30 
mg higher than that required according to the patient’s 
GFR; this was largely due to an option to increase the 
prescribed dose in patients with a large surface area. Car­
boplatin dose escalations following assessment of first- 
course blood count nadirs were performed in just over 
half the patients. Thirty-one percent had just one dose 
escalation, 11% had two, and 10% had escalations 
throughout all three subsequent cycles.
In patients treated with CEB, the validity of carboplatin 
dose was investigated in a number of ways. In comparing 
treatment failures with patients continuously disease-free, 
the mean cycle 1 carboplatin dose per square meter was 
378 mg versus 391 mg (P -  .14). Fifty-three percent 
versus 51 %, respectively, had dose escalations. The cycle
1 blood count nadirs were lower in patients who have not 
failed to respond (x2 [trend], P = .03 for platelets, .04 for 
WBCs) (Table 4). There were no significant differences in 
WBC and platelet nadirs in the first cycle of CEB compar­
ing those whose carboplatin dose was calculated from a 
creatinine clearance or an EDTA clearance, and also there 
was no difference in failure rates (28% v 26.2%; x 2 =
0.98; P = .75). In summary, there was no evidence that 
CEB treatment failures were incorrectly dosed in compar­
ison to those who did not fail to respond. There is some 
evidence that higher nadir counts were associated with 
increased failure rates, and the possibility that this relates
1847
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Fig 1. T E 09/30896 . Failure-free survival by treatment allocated.
also to BEP patients cannot be excluded in view of the 
small number of BEP failures.
P < .0001). Mild mucosal toxicity was more common in 
BEP patients (x 2 [trend], P = .07); however, there was
To assess carboplatin dose-response, patients were split no difference in the incidence of “clinically distressing”
into three groups of approximately equal size; there was 
no consistent trend in failure rates (Table 5).
Toxicity
Toxicity on treatment is listed in Table 6. Thrombocy­
topenia was more pronounced in CEB patients (x 2 [trend],
Table 3. Current Status of Patients by Initial Chemotherapy Allocated
Allocated
Treatment
Status BEP CEB
Total failures 30 79
Early death 1 1
Incomplete response to initial chemotherapy (lack of
marker response) 3 8
Viable (undifferentiated) tumor resected 11 24
Relapse 15 46
Dead 10 26
Time from failure to death, months
Median 8 11
Range 0-37 0-32
Alive 20 53
Time since failure, months
Median 29 23
Range 3-69 0-62
Continuously disease-free 270 219
Total 300 298
mucosal toxicity. Sensory deficit was also more common 
with BEP (x2 [trend], P = .001), but was mainly mild. 
Audiometry was performed in only a small subset of 
MRC patients; some degree of hearing loss was found in
11 of 39 BEP patients and two of 28 CEB patients (P = 
.07). As expected, CEB was associated with fewer days 
in hospital during the protocol chemotherapy; 88% of 
patients allocated CEB had fewer than 14 days in hospital 
compared with 41% of patients allocated to receive BEP.
Renal toxicity is listed in Table 7. GFR decreased from 
a median of 123 mL/min prechemotherapy to 110 mL/ 
min approximately 4 weeks after completion of induction 
chemotherapy with BEP, and to 120 mL/min after com­
pletion of CEB, a statistically significant difference 
(Mann-Whitney P — .02). This difference appears to be 
maintained; taking the maximum GFR recorded at any 
time more than 12 months from randomization (9 months 
from completion of treatment), the median value for BEP 
was 109 mL/min and for CEB, 121 mL/min (Mann-Whit­
ney P -  .05).
DISCUSSION
*
This trial has demonstrated that combination chemo­
therapy based on BEP is superior to the combination of 
CEB in the doses and schedules used. Patients allocated
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to receive CEB had significantly worse failure-free and 
overall survival and, additionally, nadir thrombocyto­
penia was more pronounced. The mild mucosal toxicity, 
peripheral sensory neuropathy, and audiometric evidence 
of hearing loss were more marked in patients who re­
ceived cisplatin. These toxicities were all mild in severity. 
Renal toxicity was more marked in patients allocated to
Table A, Treatment Effect and Myelosuppression
Treatment Failures
No Yes
Cycle 1 Nadirs No. % No. %
CEB patients 
Platelets (X  109/L)
>  150 109 53 43 ÓÌ
90-150 54 17 23 33
<  90 41 20 4 &
WBC (X  109/L)
>  2.0 160 79 03 90
-  2.0 42 21 7 10
BEP patients 
Platelets (X  109A)
>  150 183 78 21 81
90-150 41 18 5 19
<  90 10 4 0 0
WBC (X  109/L)
>  2.0 209 89 25 86
s 2 .0 25 11 1 4
receive cisplatin; however, there was only a minor de­
crease in the median GFR assessed at 1 month and again 
more than 9 months after the completion of cisplatin- 
based chemotherapy.
The inferior failure-free survival in patients treated 
with CEB is consistent with the results of a multicenter 
randomized phase III clinical trial that compared EC with 
EP.12 This trial was based on 270 patients with good-risk 
germ cell tumors randomized to receive four cycles of 
either EP or EC with an etoposide dose in all patients of 
100 mg/m2 on days 1 through 5, cisplatin 20 mg/m2 on 
days 1 through 5, and carboplatin at a fixed dose of 500 
mg/m2 on day 1. In this trial, the EC recycling interval 
was 28 days, whereas the EP recycling interval was 21 
days. One interpretation of the inferior results in the car-
Table 5. Carboplatin Dose-Response
Carboplatin Dose
No. of 
Failures/ 
Patients
Crude 
Failure 
Rate {%} Test Statistic
Cycle 1 dose received (mg)
<  700 18/69 26 X2 (trend) = 0,75
700-800 28/85 33 P= .39
>  800 15/75 20
Cycle 1 dose received (mg/m2)
<  350 18/58 31 X2 (trend) = 0.44
350-400 20/81 25 II cn
>  400 23/67 26
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Table 6. Toxicity During Treatment
Allocated Treatment
BEP CEB
During Treatment No. % No. %
Nadir WBC (X 109/U
>  2 154 75 137 65
1.0-2.0 47 23 72 34
<  1.0 3 1 1 0
< 1 . 0  + sepsis 1 0 0 0
Nadir platelets (X 109/L)
>  150 142 69 75 36
90-150 43 21 68 32
50-89 18 9 42 20
<  50 2 1 25 12
Swelling hands/feet
None 205 95 209 95
Minor 8 4 8 4
Clinically distressing 2 1 3 1
Mucosal
None 169 79 190 87
Minor 42 20 24 11
Clinically distressing 4 2 5 2
Motor
None 204 95 211 97
Minor 9 4 7 3
Clinically distressing 1 0 0 0
Sensory
None 179 84 205 94
Minor 30 14 12 6
Clinically distressing 4 2 1 0
Audiometry
Normal hearing 28 72 27 93
High tone loss, 8 kHz 9 23 1 3
High tone loss, 2 kHz 2 5 1 3
Total (MRC patients only) 236 236 472
boplatin arm was this was due to the long intercycle 
interval. The trial demonstrated that 24% of patients who
subcategories of response to allow a comparison between 
the trials. Using the Memorial/SWOG definition, the 
MRC/EORTC complete response rates were 91% (264 
of 290) for BEP and 87% (251 of 290) for CEB if nonas­
sessable (PMNM) patients were included in the denomi­
nator. Complete response rates were 98.5% (264 of 268) 
for BEP and 96.5% (252 of 260) for CEB in assessable 
patients, compared with 90% for EP and 88% for EC in 
the Memorial/SWOG report. However, as shown in Table
1, our use of primary chemotherapy for many patients 
with small-volume retroperitoneal metastases led to a 
higher proportion of those in the MRC/EORTC trial hav­
ing minimal disease on the Indiana University classifica­
tion (85% v 58% in the Memorial/SWOG trial), which 
might also influence the response rates.
The results appear in contrast to the pilot study of 
carboplatin-based therapy in germ cell tumors.9,14 The 
major differences between the pilot study and the random­
ized trial are that the pilot study was performed within a 
single institution by a specialized unit and was based on 
a higher bleomycin dose and dose-intensity, namely, 30 
U/wk to a total of 360 U. There is evidence for improved 
survival of patients with germ cell tumors treated in spe­
cialized centers15; however, all centers that contributed to 
this trial had experience and expertise in the chemother­
apy of germ cell tumors. When this trial was designed, 
evidence was suggesting that bleomycin had little role 
in the combination chemotherapy of patients with good- 
prognosis germ cell tumors.3,10,16 Subsequent studies have 
emphasized the importance of bleomycin, especially in 
the context of modifications of the standard four cycles 
of BEP, such as the use of vinblastine rather than etopo- 
side17 or a reduction in the total number of treatment 
cycles,18 It is conceivable therefore that the inferior effi-
received carboplatin experienced an incomplete response cacy of CEB found by the randomized trial was compen- 
or relapse, compared with 13% of those allocated to re- sated for in the pilot study by the use of full-dose weekly
ceive cisplatin (P — .02). No difference in overall survival 
was evident at the time of the report.12
bleomycin.
There was concern that the requirement for accurate
The etoposide dose was higher at 2,000 mg/m per assessment of GFR as a basis for carboplatin dosimetry 
cycle in the Memorial Sloan-Kettering/SWOG trial of EP might have led to inadvertent underdosing with car-
versus EC than in the MRC/EORTC trial (1,440 mg/m2); 
however, there is no clear evidence that this had an impact 
on response. Before response rates are compared, it 
should be emphasized that the Memorial/SWOG report 
included within the definition of complete response those 
patients who had complete resection of undifferentiated 
cancer postchemotherapy (classified as incomplete re­
sponse by the MRC/EORTC). Also, in our report on the 
MRC/EORTC trial, almost 10% of patients were classi­
fied as not assessable for response because of persisting 
masses with normal markers (PMNM). Table 2 classifies
boplatin. Previous studies that analyzed carboplatin dose- 
response suggested the relevance of accurate dosimetry,9
Table 7. Renal Toxicity
Allocated Treatment
BEP CEB
Time Median Range Median Range
Pretreatment
4 weeks postchemotherapy 
>  9 months postchemotherapy
123
110
109
69-252
45-182
65-169
123
120
121
58-213
75-198
55-279
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An analysis of 121 patients treated with CEB at the Royal the renal effects of cisplatin influencing the excretion
Mars den Hospital demonstrated that at a carboplatin dose 
of >  400 mg/m2, two of 58 patients failed to respond to 
treatment, compared with seven of 63 patients who re­
ceived a dose less than this. Similarly, if dose was based 
on GFR, a serum concentration X time of 5.0 mg/mL X 
minutes was associated with failure in two of 74 patients 
(2.7%), compared with seven of 47 patients (14.9%) 
treated to a serum concentration X time less than this (P 
^  .05). The failure rate increased to 26% for doses less 
than 4.5 mg/mL X minutes. To seek evidence for car-
of etoposide. This has been shown not to occur with 
carboplatin.19
This trial confirms the efficacy of the combination of 
BEP, even when associated with the relatively low total 
doses of 120 U of bleomycin and 1,440 mg/m2 of etopo­
side. This arm of the trial was associated with only 10 
disease-related deaths among 300 allocated patients, a
survival rate at 3 years of 97%, and with toxicities that 
were both uncommon and mild. Since bleomycin-induced 
pulmonary toxicity continues to be a problem in the man-
boplatin underdosing, we analyzed dose and extent of agement of testicular tumors, the efficacy of the BEP
myelosuppression in patients treated with CEB, compar- schedule that contains a total bleomycin dose of only 120
ing those who failed to respond after chemotherapy with U is of interest. In good-prognosis patients with germ cell
those who did not fail to respond (Table 5). There were 
no significant differences, which suggests that inadequate
tumors defined using different criteria, four cycles of EP 
have also achieved high control rates and survival.3,12,16 
carboplatin dose was not the cause of the increased failure Thus, to define the optimal regimen for patients with
rate. Also, the complete response rate for CEB was not 
significantly different from that reported for EC (with 
carboplatin at 500 mg/m2) in the Memorial/SWOG trial.12 
However, it is noteworthy that the overall level of myelo­
suppression that resulted from CEB was low (Table 6). 
In other tumor types, such as ovarian cancer, correlations 
between carboplatin-induced myelosuppression and treat­
ment outcome have been noted,19 and it is conceivable 
that a higher initial carboplatin dose might have been 
associated with improved efficacy of the combination. 
Additionally, it is conceivable that there is pharmacoki-
good-prognosis metastatic germ cell tumors, key clinical 
trial results include the inferiority of carboplatin com­
pared with cisplatin in this and a previous report12 and 
the equivalence of EP and BEP when each are given to 
total of four cycles,19 but the inferiority of EP compared 
with BEP when each is given to a total of only three 
cycles.18 The MRC and the EORTC are now cooperating 
on a prospective randomized trial with the main aim to 
confirm the previous report4 that three cycles of BEP 
chemotherapy are as effective as four cycles in good- 
prognosis patients. In this trial, all patients will receive
netic interaction between cisplatin and etoposide, with bleomycin 30 U/wk for 9 cycles.
APPENDIX
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